| |  Online-Ressource |
|---|
| Verfasst von: | Reiter, Andreas [VerfasserIn]  |
|---|
| | Gotlib, Jason [VerfasserIn] |
|---|
| | Álvarez-Twose, Iván [VerfasserIn] |
|---|
| | Radia, Deepti H. [VerfasserIn] |
|---|
| | Lübke, Johannes [VerfasserIn] |
|---|
| | Bobbili, Priyanka J. [VerfasserIn] |
|---|
| | Wang, Aolin [VerfasserIn] |
|---|
| | Norregaard, Chelsea [VerfasserIn] |
|---|
| | Dimitrijevic, Saša [VerfasserIn] |
|---|
| | Sullivan, Erin [VerfasserIn] |
|---|
| | Louie-Gao, Melinda [VerfasserIn] |
|---|
| | Schwaab, Juliana [VerfasserIn] |
|---|
| | Galinsky, Ilene A. [VerfasserIn] |
|---|
| | Perkins, Cecelia [VerfasserIn] |
|---|
| | Sperr, Wolfgang R. [VerfasserIn] |
|---|
| | Sriskandarajah, Priya [VerfasserIn] |
|---|
| | Chin, Andi [VerfasserIn] |
|---|
| | Sendhil, Selvam R. [VerfasserIn] |
|---|
| | Duh, Mei Sheng [VerfasserIn] |
|---|
| | Valent, Peter [VerfasserIn] |
|---|
| | DeAngelo, Daniel J. [VerfasserIn] |
|---|
| Titel: | Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis |
|---|
| Titelzusatz: | myelodysplastic syndrome |
|---|
| Verf.angabe: | Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Lübke, Priyanka J. Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Andi Chin, Selvam R. Sendhil, Mei Sheng Duh, Peter Valent and Daniel J. DeAngelo |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 05 July 2022 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 31.10.2023 |
|---|
| Titel Quelle: | Enthalten in: Leukemia |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 36(2022), 8, Seite 2108-2120 |
|---|
| ISSN Quelle: | 1476-5551 |
|---|
| Abstract: | Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198) and Phase 2 PATHFINDER (NCT03580655) trials (N = 176) and patients treated with best available therapy (BAT; N = 141). A multi-center, observational, retrospective chart review study was conducted at six study sites (four European, two American) to collect data from patients with AdvSM who received BAT; these data were pooled with data from EXPLORER and PATHFINDER. Comparisons between outcomes of OS, duration of treatment (DOT), and maximum reduction in serum tryptase were conducted between the treatment cohorts, with adjustment for key covariates. The results indicated that the avapritinib cohort had significantly better survival (adjusted hazard ratio (HR) (95% confidence interval (CI)): 0.48 (0.29, 0.79); p = 0.004) and significantly longer DOT (HR: 0.36 (0.26, 0.51); p < 0.001) compared to the BAT cohort. Additionally, the mean difference in percentage maximum reduction in serum tryptase levels was 60.3% greater in the avapritinib cohort (95% CI: −72.8, −47.9; p < 0.001). With no randomized controlled trials comparing avapritinib to BAT, these data offer crucial insights into the improved efficacy of avapritinib for the treatment of AdvSM. |
|---|
| DOI: | doi:10.1038/s41375-022-01615-z |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1038/s41375-022-01615-z |
|---|
| | kostenfrei: Volltext: http://www.nature.com/articles/s41375-022-01615-z |
|---|
| | DOI: https://doi.org/10.1038/s41375-022-01615-z |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Cancer therapy |
|---|
| | Targeted therapies |
|---|
| K10plus-PPN: | 1868839656 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis / Reiter, Andreas [VerfasserIn]; 05 July 2022 (Online-Ressource)
Zurück zur Trefferübersicht und Suche
